ALPHAHELIX MOL.DIAGN. SK1 (4MB) - Net Assets
Based on the latest financial reports, ALPHAHELIX MOL.DIAGN. SK1 (4MB) has net assets worth €6.65 Million EUR (≈ $7.77 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€18.96 Million ≈ $22.17 Million USD) and total liabilities (€12.31 Million ≈ $14.39 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See ALPHAHELIX MOL.DIAGN. SK1 balance sheet independence to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €6.65 Million |
| % of Total Assets | 35.07% |
| Annual Growth Rate | -68.23% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 15.44 |
ALPHAHELIX MOL.DIAGN. SK1 - Net Assets Trend (2022–2025)
This chart illustrates how ALPHAHELIX MOL.DIAGN. SK1's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 4MB company net worth.
Annual Net Assets for ALPHAHELIX MOL.DIAGN. SK1 (2022–2025)
The table below shows the annual net assets of ALPHAHELIX MOL.DIAGN. SK1 from 2022 to 2025. Also explore ALPHAHELIX MOL.DIAGN. SK1 annual equity growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €637.18K ≈ $744.93K |
-84.74% |
| 2024-12-31 | €4.18 Million ≈ $4.88 Million |
-59.90% |
| 2023-12-31 | €10.41 Million ≈ $12.18 Million |
-47.64% |
| 2022-12-31 | €19.89 Million ≈ $23.25 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ALPHAHELIX MOL.DIAGN. SK1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1035.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €19.51 Million | 3061.42% |
| Total Equity | €637.18K | 100.00% |
ALPHAHELIX MOL.DIAGN. SK1 Competitors by Market Cap
The table below lists competitors of ALPHAHELIX MOL.DIAGN. SK1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Migo Opportunities Trust PLC
LSE:MIGO
|
$881.29K |
|
Nicolas Miguet et Associes SA
PA:MLNMA
|
$882.96K |
|
GenixPharmaceucticals Corporation
V:GENX
|
$885.77K |
|
Intercede Group
LSE:IGP
|
$889.40K |
|
Enersize Oy
ST:ENERS
|
$877.64K |
|
Spectra Systems Corp
LSE:SPSY
|
$877.07K |
|
Future Enterprises Limited
NSE:FELDVR
|
$872.94K |
|
GIGLIO GROUP S.P.A. O.N.
F:5JR
|
$872.65K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ALPHAHELIX MOL.DIAGN. SK1's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,176,518 to 637,176, a change of -3,539,342 (-84.7%).
- Net loss of 3,539,343 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-3.54 Million | -555.47% |
| Other Changes | €1.00 | +0.0% |
| Total Change | €- | -84.74% |
Book Value vs Market Value Analysis
This analysis compares ALPHAHELIX MOL.DIAGN. SK1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.18x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.04x to 1.18x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | €0.31 | €0.01 | x |
| 2023-12-31 | €0.16 | €0.01 | x |
| 2024-12-31 | €0.06 | €0.01 | x |
| 2025-12-31 | €0.01 | €0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ALPHAHELIX MOL.DIAGN. SK1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -555.47%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -10.94%
- • Asset Turnover: 2.30x
- • Equity Multiplier: 22.05x
- Recent ROE (-555.47%) is below the historical average (-211.53%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -11.18% | -6.48% | 1.19x | 1.45x | €-4.21 Million |
| 2023 | -90.99% | -36.31% | 1.37x | 1.83x | €-10.52 Million |
| 2024 | -188.49% | -31.37% | 1.63x | 3.68x | €-8.29 Million |
| 2025 | -555.47% | -10.94% | 2.30x | 22.05x | €-3.60 Million |
Industry Comparison
This section compares ALPHAHELIX MOL.DIAGN. SK1's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $3,615,099,175
- Average return on equity (ROE) among peers: -12.03%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ALPHAHELIX MOL.DIAGN. SK1 (4MB) | €6.65 Million | -11.18% | 1.85x | $879.62K |
| IZOTROPIC CORP. (1R3) | $-3.07 Million | 0.00% | 0.00x | $8.79 Million |
| HANGZHOU TIGERMED CO. H 1 (5HZ1) | $22.68 Billion | 8.85% | 0.21x | $713.97 Million |
| Check-Cap Ltd (7CC) | $50.69 Million | -33.94% | 0.10x | $9.20 Million |
| INTERGRATED DIA.H DL 025 (8I8) | $4.13 Billion | 30.56% | 1.08x | $286.80 Million |
| GENETIC ANALYSIS NK -60 (8V8) | $27.08 Million | -42.15% | 0.94x | $2.36 Million |
| GENINCODE PLC LS -01 (9PL) | $7.90 Million | -70.37% | 0.49x | $6.02 Million |
| INOVIQ LTD. (EGQ0) | $19.62 Million | -45.73% | 0.10x | $14.07 Million |
| Eurofins Scientific SE (ESF0) | $4.68 Billion | 16.73% | 1.00x | $11.18 Billion |
| ICON Public Limited Company (IJF) | $945.17 Million | 27.74% | 0.93x | $7.52 Billion |
About ALPHAHELIX MOL.DIAGN. SK1
Level Bio AB (publ) manufactures and distributes cutting-edge solutions in the Nordic region and internationally. It develops and manufactures diagnostic kits for the clinical market, as well as act as a distributor and full service partner to molecular biology labs in the Nordics. The company was formerly known as AlphaHelix Molecular Diagnostics AB (publ) and changed its name to Level Bio AB (p… Read more